103 related articles for article (PubMed ID: 17163281)
1. Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.
Alabbadi I; Crealey G; Scott M; Baird S; Trouton T; Mairs J; McElnay J
Clin Drug Investig; 2006; 26(9):485-94. PubMed ID: 17163281
[TBL] [Abstract][Full Text] [Related]
2. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.
Janknegt R; Steenhoek A
Drugs; 1997 Apr; 53(4):550-62. PubMed ID: 9098659
[TBL] [Abstract][Full Text] [Related]
3. ACE inhibitors for the treatment of hypertension drug selection by means of the SOJA method.
Edgar L; Hogg A; Scott M; Timoney M; Mc Elnay J; Mairs J; Janknegt R
Rev Recent Clin Trials; 2011 Jan; 6(1):69-93. PubMed ID: 20868351
[TBL] [Abstract][Full Text] [Related]
4. Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.
Al-Badriyeh D; Alabbadi I; Fahey M; Al-Khal A; Zaidan M
Clin Ther; 2016 May; 38(5):1158-73. PubMed ID: 27021610
[TBL] [Abstract][Full Text] [Related]
5. Hypnotics. Drug selection by means of the System of Objectified Judgement Analysis (SOJA) method.
Janknegt R; van der Kuy A; Declerck G; Idzikowski C
Pharmacoeconomics; 1996 Aug; 10(2):152-63. PubMed ID: 10163418
[TBL] [Abstract][Full Text] [Related]
6. System of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision making.
Janknegt R; Scott M; Mairs J; Timoney M; McElnay J; Brenninkmeijer R
Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S5-14. PubMed ID: 17931079
[TBL] [Abstract][Full Text] [Related]
7. Formulary management of ACE inhibitors.
Gerbrandt KR; Yedinak KC
Pharmacoeconomics; 1996 Dec; 10(6):594-613. PubMed ID: 10164060
[TBL] [Abstract][Full Text] [Related]
8. Using health outcomes data to inform decision-making: formulary committee perspective.
Janknegt R
Pharmacoeconomics; 2001; 19 Suppl 2():49-52. PubMed ID: 11700789
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.
Janknegt R
Pharmacoeconomics; 1994 Jul; 6(1):15-33. PubMed ID: 10147351
[TBL] [Abstract][Full Text] [Related]
10. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
[TBL] [Abstract][Full Text] [Related]
11. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
12. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
Counterweight Project Team
J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
[TBL] [Abstract][Full Text] [Related]
13. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
[TBL] [Abstract][Full Text] [Related]
14. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
Diaby V; Lachaine J
Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
[TBL] [Abstract][Full Text] [Related]
15. Application of SOJA and InforMatrix in practice: interactive web and workshop tools.
Brenninkmeijer R; Janknegt R
Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S49-55. PubMed ID: 17931078
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
[TBL] [Abstract][Full Text] [Related]
17. Triptans in the treatment of migraine: drug selection by means of the SOJA method.
Janknegt R
Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S15-30. PubMed ID: 17931075
[TBL] [Abstract][Full Text] [Related]
18. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
19. Formulary evaluation of third-generation cephalosporins using decision analysis.
Cano SB; Fujita NK
Am J Hosp Pharm; 1988 Mar; 45(3):566-9. PubMed ID: 3285673
[TBL] [Abstract][Full Text] [Related]
20. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Smith DG; Cerulli A; Frech FH
Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
